Quantumzyme Addresses OTC Markets Caveat Emptor Designation and Unauthorized Promotional Messages

Quantumzyme Corp., a biotechnology company specializing in computational enzyme engineering, is taking decisive action in response to its recent Caveat Emptor designation by OTC Markets Group and unauthorized promotional activities.

The company has immediately initiated contact with OTC Markets to understand and resolve the concerns leading to the designation. By retaining legal counsel and committing to a cooperative approach, Quantumzyme aims to swiftly address the issues and have the Caveat Emptor status removed.

Of significant concern is the distribution of promotional SMS text messages mentioning the company, which Quantumzyme categorically denies authorizing or endorsing. The firm has unequivocally stated it has no affiliation with the entity responsible for these messages and will fully cooperate with any regulatory reviews related to the incident.

CEO Naveen Kulkarni emphasized the company's dedication to regulatory compliance and market integrity. By proactively addressing these challenges, Quantumzyme seeks to protect its reputation and maintain transparent communication with shareholders and market participants.

The ongoing situation highlights the importance of regulatory vigilance in the biotechnology sector, where investor confidence and corporate transparency are crucial. Quantumzyme's response demonstrates a commitment to resolving potential compliance issues promptly and professionally.

As a company focused on sustainable biotransformation and green chemistry, Quantumzyme continues to prioritize its core mission of developing innovative enzyme-based solutions while navigating the complex regulatory landscape of public markets.